Logo image of PLXP

PLX PHARMA INC (PLXP) Stock Fundamental Analysis

NASDAQ:PLXP - Nasdaq - US72942A1079 - Common Stock - Currency: USD

0.087  -0.03 (-27.8%)

After market: 0.083 0 (-4.6%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to PLXP. PLXP was compared to 193 industry peers in the Pharmaceuticals industry. PLXP scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. PLXP is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year PLXP has reported negative net income.
In the past year PLXP has reported a negative cash flow from operations.
PLXP Yearly Net Income VS EBIT VS OCF VS FCFPLXP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 0 -10M -20M -30M -40M

1.2 Ratios

The profitability ratios for PLXP are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PLXP Yearly ROA, ROE, ROICPLXP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 0 1K -1K -2K

1.3 Margins

The Gross Margin of PLXP (4.46%) is comparable to the rest of the industry.
PLXP does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 4.46%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PLXP Yearly Profit, Operating, Gross MarginsPLXP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 0 -10K -20K -30K -40K -50K

More info and screens

6

2. Health

2.1 Basic Checks

PLXP does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PLXP has more shares outstanding
There is no outstanding debt for PLXP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
PLXP Yearly Shares OutstandingPLXP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 5M 10M 15M 20M 25M
PLXP Yearly Total Debt VS Total AssetsPLXP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M

2.2 Solvency

PLXP has an Altman-Z score of -12.74. This is a bad value and indicates that PLXP is not financially healthy and even has some risk of bankruptcy.
PLXP has a worse Altman-Z score (-12.74) than 81.90% of its industry peers.
PLXP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -12.74
ROIC/WACCN/A
WACC8.82%
PLXP Yearly LT Debt VS Equity VS FCFPLXP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 20M -20M 40M

2.3 Liquidity

PLXP has a Current Ratio of 4.79. This indicates that PLXP is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 4.79, PLXP is in line with its industry, outperforming 57.47% of the companies in the same industry.
A Quick Ratio of 4.28 indicates that PLXP has no problem at all paying its short term obligations.
PLXP has a Quick ratio (4.28) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.79
Quick Ratio 4.28
PLXP Yearly Current Assets VS Current LiabilitesPLXP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M

More info and screens

4

3. Growth

3.1 Past

PLXP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 68.03%, which is quite impressive.
PLXP shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -31.32%.
Measured over the past years, PLXP shows a very strong growth in Revenue. The Revenue has been growing by 233.15% on average per year.
EPS 1Y (TTM)68.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.5%
Revenue 1Y (TTM)-31.32%
Revenue growth 3Y122.02%
Revenue growth 5Y233.15%
Sales Q2Q%-94.17%

3.2 Future

PLXP is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.25% yearly.
The Revenue is expected to decrease by -36.40% on average over the next years. This is quite bad
EPS Next Y36.14%
EPS Next 2Y22.25%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-57.24%
Revenue Next 2Y-36.4%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
PLXP Yearly Revenue VS EstimatesPLXP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M
PLXP Yearly EPS VS EstimatesPLXP Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -5 -10 -15

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

PLXP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PLXP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PLXP Price Earnings VS Forward Price EarningsPLXP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PLXP Per share dataPLXP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5 -2

4.3 Compensation for Growth

PLXP's earnings are expected to grow with 22.25% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.25%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

PLXP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PLX PHARMA INC

NASDAQ:PLXP (4/12/2023, 8:00:00 PM)

After market: 0.083 0 (-4.6%)

0.087

-0.03 (-27.8%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-10 2023-03-10
Earnings (Next)05-11 2023-05-11
Inst Owners0.01%
Inst Owner Change0%
Ins Owners5.62%
Ins Owner Change0%
Market Cap2.53M
Analysts43.33
Price Target11.22 (12796.55%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)28.94%
Min EPS beat(2)24.72%
Max EPS beat(2)33.16%
EPS beat(4)4
Avg EPS beat(4)54.68%
Min EPS beat(4)24.72%
Max EPS beat(4)113.72%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-78.74%
Min Revenue beat(2)-86.6%
Max Revenue beat(2)-70.89%
Revenue beat(4)0
Avg Revenue beat(4)-50.16%
Min Revenue beat(4)-86.6%
Max Revenue beat(4)-19.39%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.56
P/FCF N/A
P/OCF N/A
P/B 0.1
P/tB 0.11
EV/EBITDA N/A
EPS(TTM)-1.02
EYN/A
EPS(NY)-1.12
Fwd EYN/A
FCF(TTM)-2.04
FCFYN/A
OCF(TTM)-2.04
OCFYN/A
SpS0.16
BVpS0.9
TBVpS0.83
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 4.46%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.14
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.79
Quick Ratio 4.28
Altman-Z -12.74
F-Score2
WACC8.82%
ROIC/WACCN/A
Cap/Depr(3y)77.78%
Cap/Depr(5y)471.67%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)68.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.5%
EPS Next Y36.14%
EPS Next 2Y22.25%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-31.32%
Revenue growth 3Y122.02%
Revenue growth 5Y233.15%
Sales Q2Q%-94.17%
Revenue Next Year-57.24%
Revenue Next 2Y-36.4%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-172.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-337.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-344.13%
OCF growth 3YN/A
OCF growth 5YN/A